Description: Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Home Page: www.ionispharma.com
2855 Gazelle Court
Carlsbad,
CA
92010
United States
Phone:
760 931 9200
Officers
| Name | Title |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director |
| Ms. Elizabeth L. Hougen | Exec. VP of Fin. & CFO |
| Ms. Onaiza Cadoret-Manier | Exec. VP, Chief Global Product Strategy & Operations Officer |
| Mr. Patrick R. O'Neil Esq. | Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. |
| Dr. Stanley T. Crooke | Scientific Advisor |
| Ms. B. Lynne Parshall Esq., J.D. | Sr. Strategic Advisor & Director |
| Dr. Eric E. Swayze Ph.D. | Exec. VP of Research |
| Mr. Joel Edwards | VP of Corp. Operations |
| Mr. Darren Gonzales | Chief Accounting Officer & Sr. VP |
| Dr. C. Frank Bennett | Exec. VP & Chief Scientific Officer |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 90.0901 |
|---|---|
| Trailing PE: | 597.5833 |
| Price-to-Book MRQ: | 9.0206 |
| Price-to-Sales TTM: | 5.9044 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 660 |